Health and Healthcare
Genentech Expands Stock Buybacks (DNA)
Published:
Last Updated:
Genentech, Inc. (NYSE:DNA) has announced that the biotech giant has authorized the extension of its current stock repurchase program through June 30, 2009 and it amended the current repurchase program.
It is increasing the maximum number of shares that can be repurchased to a total of 150 million shares from an amount of 100 million shares, which in effect is increasing the total value of shares that can be repurchased to $10 Billion from $8 Billion. These share repurchases can be in the open market or in privately negotiated transactions from time to time at management’s discretion. It also may used derivative securities to effect repurchases.
The repurchased stock is meant to offset dilution caused by the issuance of shares in connection with Genentech’s employee stock plans, which is generally less impressive than when companies go out and retire shares or stick them in the treasury for future acquisitions.
You can join our open email distribution list to hear about key calls, buybacks, IPO’s, special financings, restructurings and more.
Jon C. Ogg
April 15, 2008
Jon Ogg produces the Special Situation Investing Newsletter. He can be reached at [email protected] and he does not own securities in the companies he covers.
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.